Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval
Provided by
Dow Jones
By Denny Jacob
Bristol Myers Squibb disclosed that the U.S. Food and Drug Administration granted accelerated approval of Augtyro.
The biopharmaceutical product developer said the approval is based on results from a Phase 1/2 study which evaluated Augtyro in adult patients with neurotrophic tyrosine receptor kinase positive solid tumors.
The treatment's approval applies to adult and pediatric patients ages 12 years and up with solid tumors that have a neurotrophic tyrosine receptor kinase gene fusion, among other factors.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
June 13, 2024 17:23 ET (21:23 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations